Age-related macular degeneration (AMD) is a leading cause of vision loss in people aged 50 and older, affecting over 11 million individuals in the U.S. and more than 196 million globally. It impacts the macula, the central part of the retina responsible for sharp vision. AMD develops in two forms: dry AMD, which accounts for 85-90% of cases and progresses slowly, and wet AMD, a less common but aggressive form responsible for 90% of severe vision loss. Risk increases significantly with age, affecting nearly 30% of those aged 75 and older, and smokers are 2-4 times more likely to develop the condition. Symptoms include blurry central vision, difficulty seeing in low light, distorted lines, and trouble recognizing faces. Early diagnosis through comprehensive eye exams is critical to managing AMD and slowing its progression, with projections indicating the number of global cases could rise to 288 million by 2040.
Patients are the experts in their condition and advocacy groups provide a platform for patient voices. Working directly with these communities is the key to pushing research forward in an inclusive way.
We’ve committed to having 500,000 conversations in the next three years, to equip ourselves and our Pharma partners with the insights needed to increase predictability.
Read more...
The ever-growing investment in advocacy doesn’t appear to be slowing down, and research is certainly seeing the benefits. Which at the end of the day, means better patient care and more options for patients
Read more...
We’re ready to keep forming links between our Advocacy friends and Pharma partners, so these fruitful relationships continue to evolve beyond the study-to-study view.
Read more...